Reduced dose ocrelizumab outcome study

Ocrelizumab is an effective therapy for the neuroinflammatory disorder multiple sclerosis. Because of the risks of infection with long-term use of this B-cell depleting therapy, particularly in relation to COVID-19, a reduced dose of 300mg, instead of the full dose of 600mg, has been routinely used after the first 2 years at GCUH. The aim of this project is to study clinical and laboratory parameters comparing outcomes on reduced dose ocrelizumab versus full dose in a cohort of people with multiple sclerosis on this therapy. Specifically, we would like to examine B-cell counts in the blood, relapse frequency and disability measures (EDSS) to ensure that these clinical outcomes are not worse on the lower dose.